Zymeworks: Royalty Cashflow Today, ADC Upside Tomorrow
Zymeworks ($ZYME) combines royalty revenue from licensed assets with a deep antibody-drug conjugate (ADC) pipeline that now carries real clinical momentum. The market prices the company like a high-growth commercial biopharma at a $1.85B market cap, but cash-like royalties, recent leadership hires aligned with deal execution, and Fast Track status …